课题基金 / 基金详情

CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA

CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
CS96 209 SCH56592 与氟康唑治疗口咽念珠菌的比较
批准号：
6291146
负责人：
JOSEPH WHEAT
金额：
$0.04万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6291146
关键词：
HIV infections antifungal agents candidiasis chemotherapy clinical research dosage drug adverse effect drug screening /evaluation human subject human therapy evaluation

项目摘要

项目成果

JOSEPH WHEAT的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This study will be carried out to assess safety, tolerability, and efficacy parameters in HIV-positive patients with oropharyngeal candidiasis (OPC), and also to select a dose or doses prior to initiation of studies in patients with systemic fungal infections. The primary objective: Demonstration of the clinical efficacy of the highest dose of SCH 56592.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PHASE II PLACEBO CONTROLLED TRIAL OF RECOMBINANT HUMAN GM CSF
AMBISOME VS AMPHOTERICIN B FOLLOWED BY FLUCONAZOLE IN TREATMENT OF MENINGITIS
CS96 209 SCH56592 VERSUS FLUCONAZOLE IN THE TREATMENT OF OROPHARYNGEAL CANDIDA
PHASE II TRIAL OF MEGESTROL ACETATE AND TESTOSTERONE
海外基金